Medication-overuse headache: A review

Journal of Pain Research

Volumn 7, Issue , 2014, Pages 359-366

  Kristoffersen, Espen Saxhaug ^a,b   Lundqvist, Christofer ^a  

^a AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Chronic headache; Dependence; Medication overuse headache; Migraine

Indexed keywords

ANALGESIC AGENT; CAFFEINE; CODEINE; ERGOTAMINE; MORPHINE; OPIATE; PARACETAMOL; PLACEBO; PREDNISOLONE; TRANQUILIZER; TRIPTAN DERIVATIVE;

DETOXIFICATION; DISEASE CLASSIFICATION; DRUG ABUSE; DRUG DEPENDENCE; DRUG INDUCED HEADACHE; DRUG USE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; INCIDENCE; NONHUMAN; PATHOGENESIS; PREVALENCE; QUALITY OF LIFE; RELAPSE; REVIEW; RISK FACTOR; WITHDRAWAL SYNDROME;

EID: 84903376404     PISSN: 11787090     EISSN: None     Source Type: Journal    
DOI: 10.2147/JPR.S46071     Document Type: Review

References (169)

1. Jensen R, Stovner LJ. Epidemiology and comorbidity of headache. Lancet Neurol. 2008;7(4):354-361.
2. Linde M, Gustavsson A, Stovner LJ, et al. The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol. 2012;19(5):703-711.
3. Stovner L, Hagen K, Jensen R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007;27(3):193-210.
4. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163-2196.
5. Aaseth K, Grande RB, Kvaerner KJ, Gulbrandsen P, Lundqvist C, Russell MB. Prevalence of secondary chronic headaches in a population-based sample of 30-44-year-old persons. The Akershus study of chronic headache. Cephalalgia. 2008;28(7):705-713.
6. Grande RB, Aaseth K, Gulbrandsen P, Lundqvist C, Russell MB. Prevalence of primary chronic headache in a population-based sample of 30-to 44-year-old persons. The Akershus study of chronic headache. Neuroepidemiology. 2008;30(2):76-83.
7. Lantéri-Minet M, Auray J P, El Hasnaoui A, et al. Prevalence and description of chronic daily headache in the general population in France. Pain. 2003;102(1/2):143-149.
8. Castillo J, Munoz P, Guitera V, Pascual J. Kaplan Award 1998. Epidemiology of chronic daily headache in the general population. Headache. 1998;39(3):190-196.
9. Headache Classifcation Committee of the International Headache Society. The International Classifcation of Headache Disorders. 3rd ed (beta version). Cephalalgia. 2013;33(9):629-808.
10. Latinovic R, Gulliford M, Ridsdale L. Headache and migraine in primary care: consultation, prescription, and referral rates in a large population. J Neurol Neurosurg Psychiatry. 2006;77(3):385-387.
11. Ridsdale L, Clark LV, Dowson AJ, et al. How do patients referred to neurologists for headache differ from those managed in primary care? Br J Gen Pract. 2007;57(538):388-395.
12. Patterson VH, Esmonde TF. Comparison of the handling of neurological outpatient referrals by general physicians and a neurologist. J Neurol Neurosurg Psychiatry. 1993;56(7):830.
13. Zwart JA, Dyb G, Hagen K, Svebak S, Stovner LJ, Holmen J. Analgesic overuse among subjects with headache, neck, and low-back pain. Neurology. 2004;62(9):1540-1544.
14. Zwart JA, Dyb G, Hagen K, et al. Analgesic use: a predictor of chronic pain and medication overuse headache. Neurology. 2003;61(2): 160-164.
15. Eggen AE. The Tromso Study: frequency and predicting factors of analgesic drug use in a free-living population (12-56 years). J Clin Epidemiol. 1993;46(11):1297-1304.
16. Antonov KI, Isacson DG. Prescription and nonprescription analgesic use in Sweden. Ann Pharmacother. 1998;32(4):485-494.
17. Mehuys E, Paemeleire K, Van Hees T, et al. Self-medication of regular headache: a community pharmacy-based survey. Eur J Neurol. 2012;19(8):1093-1099.
18. Porteous T, Bond C, Hannaford P, Sinclair H. How and why are non-prescription analgesics used in Scotland? Fam Pract. 2005;22(1): 78-85.
19. Hargreave M, Andersen T V, Nielsen A, Munk C, Liaw KL, Kjaer SK. Factors associated with continuous regular analgesic use - a population-based study of more than 45,000 Danish women and men 18-45 years of age. Pharmacoepidemiol Drug Saf. 2010;19(1):65-74.
20. Horton BT, Peters GA. Clinical manifestations of excessive use of ergotamine preparations and mangement of withdrawal effect: report of 52 cases. Headache. 1963;2:214-227.
21. Peters GA, Horton BT. Headache: with special reference to the excessive use of ergotamine preparations and withdrawal effects. Proc Staff Meet Mayo Clin. 1951;26(9):153-161.
22. Peters GA, Horton BT. Headache; with special reference to the excessive use of ergotamine tartrate and dihydroergotamine. J Lab Clin Med. 1950;36(6):972-973.
23. Mathew NT, Kurman R, Perez F. Drug induced refractory headache-clinical features and management. Headache. 1990;30(10):634-638.
24. Diener HC, Dichgans J, Scholz E, Geiselhart S, Gerber WD, Bille A. Analgesic-induced chronic headache: long-term results of withdrawal therapy. J Neurol. 1989;236(1):9-14.
25. Kudrow L. Paradoxical effects of frequent analgesic use. Adv Neurol. 1982;33:335-341.
26. Evers S, Jensen R; European Federation of Neurological Societies. Treatment of medication overuse headache - guideline of the EFNS headache panel. Eur J Neurol. 2011;18(9):1115-1121.
27. Diener HC, Limmroth V. Medication-overuse headache: a worldwide problem. Lancet Neurol. 2004;3(8):475-483.
28. Katsarava Z, Jensen R. Medication-overuse headache: where are we now? Curr Opin Neurol. 2007;20(3):326-330.
29. Rossi P, Jensen R, Nappi G, Allena M; COMOESTAS Consortium. A narrative review on the management of medication overuse headache: the steep road from experience to evidence. J Headache Pain. 2009;10(6):407-417.
30. Evers S, Marziniak M. Clinical features, pathophysiology, and treatment of medication-overuse headache. Lancet Neurol. 2010;9(4):391-401.
31. Kristoffersen ES, Lundqvist C. Medication-overuse headache: epidemiology, diagnosis and treatment. Ther Adv Drug Saf. 2014;5(2): 87-99.
32. Ad Hoc Committee on Classifcation of Headache of the National Institute of Health. Classifcation of headache. JAMA. 1962;179:717-718.
33. Headache Classifcation Committee of the International Headache Society. Classifcation and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8 Suppl 7:1-96.
34. Headache Classifcation Committee of the International Headache Society. The International Classifcation of Headache Disorders: 2nd ed. Cephalalgia. 2004;24 Suppl 1:9-160.
35. Cephalalgia. Erratum. Cephalalgia. 2006;26(3):360.
36. Olesen J, Bousser MG, Diener HC, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006;26(6): 742-746.
37. Silberstein SD, Olesen J, Bousser MG, et al. The International Classifcation of Headache Disorders, 2nd ed (ICHD-II) - revision of criteria for 8.2 Medication-overuse headache. Cephalalgia. 2005;25(6): 460-465.
38. Sun-Edelstein C, Bigal ME, Rapoport AM. Chronic migraine and medication overuse headache: clarifying the current International Headache Society classifcation criteria. Cephalalgia. 2009;29(4): 445-452.
39. Grazzi L, Bussone G. Medication overuse headache (MOH): complication of migraine or secondary headache? Neurol Sci. 2012; 33 Suppl 1:S27-S28.
40. Jonsson P, Hedenrud T, Linde M. Epidemiology of medication overuse headache in the general Swedish population. Cephalalgia. 2011;31(9):1015-1022.
41. Lu SR, Fuh JL, Chen WT, Juang KD, Wang SJ. Chronic daily headache in Taipei, Taiwan: prevalence, follow-up and outcome predictors. Cephalalgia. 2001;21(10):980-986.
42. Wiendels NJ, Knuistingh Neven A, Rosendaal FR, et al. Chronic frequent headache in the general population: prevalence and associated factors. Cephalalgia. 2006;26(12):1434-1442.
43. Colás R, Muñoz P, Temprano R, Gómez C, Pascual J. Chronic daily headache with analgesic overuse: epidemiology and impact on quality of life. Neurology. 2004;62(8):1338-1342.
44. Straube A, Pfaffenrath V, Ladwig KH, et al. Prevalence of chronic migraine and medication overuse headache in Germany - the German DMKG Headache Study. Cephalalgia. 2010;30(2):207-213.
45. Westergaard ML, Hansen EH, Glumer C, Olesen J, Jensen RH. Defnitions of medication-overuse headache in population-based studies and their implications on prevalence estimates: a systematic review. Cephalalgia. 2014;34(6):409-425.
46. Hagen K, Linde M, Steiner TJ, Stovner LJ, Zwart JA. Risk factors for medication-overuse headache: an 11-year follow-up study. The Nord-Trøndelag Health Studies. Pain. 2012;153(1):56-61.
47. Wang SJ, Fuh JL, Lu SR, et al. Chronic daily headache in Chinese elderly: prevalence, risk factors, and biannual follow-up. Neurology. 2000;54(2):314-319.
48. Prencipe M, Casini AR, Ferretti C, et al. Prevalence of headache in an elderly population: attack frequency, disability, and use of medication. J Neurol Neurosurg Psychiatry. 2001;70(3):377-381.
49. Wang SJ, Fuh JL, Lu SR, Juang KD. Chronic daily headache in adolescents: prevalence, impact, and medication overuse. Neurology. 2006;66(2):193-197.
50. Dyb G, Holmen TL, Zwart JA. Analgesic overuse among adolescents with headache: the Head-HUNT-Youth Study. Neurology. 2006;66(2):198-210.
51. Piazza F, Chiappedi M, Maffoletti E, Galli F, Balottin U. Medication overuse headache in school-aged children: more common than expected? Headache. 2012;52(10):1506-1510.
52. Wiendels NJ, van der Geest MC, Neven AK, Ferrari MD, Laan LA. Chronic daily headache in children and adolescents. Headache. 2005;45(6):678-683.
53. Meskunas CA, Tepper SJ, Rapoport AM, Sheftell FD, Bigal ME. Medications associated with probable medication overuse headache reported in a tertiary care headache center over a 15-year period. Headache. 2006;46(5):766-772.
54. Kristoffersen ES, Grande RB, Aaseth K, Lundqvist C, Russell MB. Management of primary chronic headache in the general population: the Akershus study of chronic headache. J Headache Pain. 2012;13(2):113-120.
55. Kristoffersen ES, Lundqvist C, Aaseth K, Grande RB, Russell MB. Management of secondary chronic headache in the general population: the Akershus study of chronic headache. J Headache Pain. 2013;14(1):5.
56. Scher AI, Lipton RB, Stewart W F, Bigal M. Patterns of medication use by chronic and episodic headache sufferers in the general population: results from the frequent headache epidemiology study. Cephalalgia. 2010;30(3):321-328.
57. Zeeberg P, Olesen J, Jensen R. Probable medication-overuse headache: the effect of a 2-month drug-free period. Neurology. 2006;66(12):1894-1898.
58. Tfelt-Hansen PC, Diener HC. Why should American headache and migraine patients still be treated with butalbital-containing medicine? Headache. 2012;52(4):672-674.
59. Limmroth V, Katsarava Z, Fritsche G, Przywara S, Diener HC. Features of medication overuse headache following overuse of different acute headache drugs. Neurology. 2002;59(7):1011-1014.
60. Creach C, Radat F, Mick G, et al. One or several types of triptan overuse headaches? Headache. 2009;49(4):519-528.
61. Jonsson P, Linde M, Hensing G, Hedenrud T. Sociodemographic differences in medication use, health-care contacts and sickness absence among individuals with medication-overuse headache. J Headache Pain. 2012;13(4):281-290.
62. Bekkelund SI, Salvesen R. Drug-associated headache is unrecognized in patients treated at a neurological centre. Acta Neurol Scand. 2002;105(2):120-123.
63. Dowson AJ. Analysis of the patients attending a specialist UK headache clinic over a 3-year period. Headache. 2003;43(1):14-18.
64. Bigal ME, Lipton RB. Excessive acute migraine medication use and migraine progression. Neurolog y. 2008;71(22):1821-1828.
65. Bigal ME, Rapoport AM, Sheftell FD, Tepper SJ, Lipton RB. Transformed migraine and medication overuse in a tertiary headache centre - clinical characteristics and treatment outcomes. Cephalalgia. 2004;24(6):483-490.
66. Lanteri-Minet M, Duru G, Mudge M, Cottrell S. Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review. Cephalalgia. 2011;31(7):837-850.
67. Wiendels NJ, van Haestregt A, Knuistingh Neven A, et al. Chronic frequent headache in the general population: comorbidity and quality of life. Cephalalgia. 2006;26(12):1443-1450.
68. Bendtsen L, Munksgaard S, Tassorelli C, et al. Disability, anxiety and depression associated with medication-overuse headache can be considerably reduced by detoxifcation and prophylactic treatment. Results from a multicentre, multinational study (COMOESTAS project). Cephalalgia. 2014;34(6):426-433.
69. Munksgaard SB, Bendtsen L, Jensen RH. Treatment-resistant medication overuse headache can be cured. Headache. 2012;52(7): 1120-1129.
70. Wallasch TM, Kropp P. Multidisciplinary integrated headache care: a prospective 12-month follow-up observational study. J Headache Pain. 2012;13(7):521-529.
71. Steiner T. Can we know the prevalence of MOH? Cephalalgia. 2014;34(6):403-404.
72. Bahra A, Walsh M, Menon S, Goadsby PJ. Does chronic daily headache arise de novo in association with regular use of analgesics? Headache. 2003;43(3):179-190.
73. Munksgaard SB, Bendtsen L, Jensen RH. Detoxifcation of medication-overuse headache by a multidisciplinary treatment programme is highly effective: a comparison of two consecutive treatment methods in an open-label design. Cephalalgia. 2012;32(11):834-844.
74. Hagen K, Vatten L, Stovner LJ, Zwart JA, Krokstad S, Bovim G. Low socio-economic status is associated with increased risk of frequent headache: a prospective study of 22718 adults in Norway. Cephalalgia. 2002;22(8):672-679.
75. Atasoy HT, Unal AE, Atasoy N, Emre U, Sumer M. Low income and education levels may cause medication overuse and chronicity in migraine patients. Headache. 2005;45(1):25-31.
76. Radat F, Creach C, Swendsen JD, et al. Psychiatric comorbidity in the evolution from migraine to medication overuse headache. Cephalalgia. 2005;25(7):519-522.
77. Zwart JA, Dyb G, Hagen K, et al. Depression and anxiety disorders associated with headache frequency. The Nord-Trondelag Health Study. Eur J Neurol. 2003;10(2):147-152.
78. Cupini LM, De MM, Costa C, et al. Obsessive-compulsive disorder and migraine with medication-overuse headache. Headache. 2009;49(7):1005-1013.
79. Cevoli S, Sancisi E, Grimaldi D, et al. Family history for chronic headache and drug overuse as a risk factor for headache chronifcation. Headache. 2009;49(3):412-418.
80. Bigal ME, Lipton RB. Overuse of acute migraine medications and migraine chronification. Curr Pain Headache Rep. 2009;13(4): 301-307.
81. Dodick DW. Debate: analgesic overuse is a cause, not consequence, of chronic daily headache. Analgesic overuse is not a cause of chronic daily headache. Headache. 2002;42(6):547-554.
82. Tepper SJ. Debate: analgesic overuse is a cause, not consequence, of chronic daily headache. Analgesic overuse is a cause of chronic daily headache. Headache. 2002;42(6):543-547.
83. Paemeleire K, Bahra A, Evers S, Matharu MS, Goadsby PJ. Medication-overuse headache in patients with cluster headache. Neurolog y. 2006;67(1):109-113.
84. Wilkinson SM, Becker WJ, Heine JA. Opiate use to control bowel motility may induce chronic daily headache in patients with migraine. Headache. 2001;41(3):303-309.
85. Cevoli S, Mochi M, Scapoli C, et al. A genetic association study of dopamine metabolism-related genes and chronic headache with drug abuse. Eur J Neurol. 2006;13(9):1009-1013.
86. Di Lorenzo C, Di Lorenzo G, Sances G, et al. Drug consumption in medication overuse headache is influenced by brain-derived neurotrophic factor Val66Met polymorphism. J Headache Pain. 2009;10(5):349-355.
87. Di Lorenzo C, Sances G, Di Lorenzo G, et al. The wolframin His611Arg polymorphism infuences medication overuse headache. Neurosci Lett. 2007;424(3):179-184.
88. Cargnin S, Viana M, Ghiotto N, et al. Functional polymorphisms in COMT and SLC6A4 genes infuence the prognosis of patients with medication overuse headache after withdrawal therapy. Eur J Neurol. Epub 2014 March 29.
89. Cupini LM, Sarchielli P, Calabresi P. Medication overuse headache: neurobiological, behavioural and therapeutic aspects. Pain. 2010;150(2):222-224.
90. De Felice M, Ossipov MH, Wang R, et al. Triptan-induced latent sensitization: a possible basis for medication overuse headache. Ann Neurol. 2010;67(3):325-337.
91. Meng ID, Dodick D, Ossipov MH, Porreca F. Pathophysiology of medication overuse headache: insights and hypotheses from preclinical studies. Cephalalgia. 2011;31(7):851-860.
92. Bongsebandhu-phubhakdi S, Srikiatkhachorn A. Pathophysiology of medication-overuse headache: implications from animal studies. Curr Pain Headache Rep. 2012;16(1):110-115.
93. Srikiatkhachorn A, Anthony M. Serotonin receptor adaptation in patients with analgesic-induced headache. Cephalalgia. 2006;16(6):419-422.
94. Srikiatkhachorn A, Maneesri S, Govitrapong P, Kasantikul V. Derangement of serotonin system in migrainous patients with analgesic abuse headache: clues from platelets. Headache. 1998;38(1):43-49.
95. Supornsilpchai W, Sanguanrangsirikul S, Maneesri S, Srikiatkhachorn A. Serotonin depletion, cortical spreading depression, and trigeminal nociception. Headache. 2006;46(1):34-39.
96. le Grand SM, Supornsilpchai W, Saengjaroentham C, Srikiatkhachorn A. Serotonin depletion leads to cortical hyperexcitability and trigemi-nal nociceptive facilitation via the nitric oxide pathway. Headache. 2011;51(7):1152-1160.
97. Supornsilpchai W, le Grand SM, Srikiatkhachorn A. Cortical hyper-excitability and mechanism of medication-overuse headache. Cepha-lalgia. 2010;30(9):1101-1109.
98. Supornsilpchai W, le Grand SM, Srikiatkhachorn A. Involvement of pro-nociceptive 5-HT2A receptor in the pathogenesis of medication-overuse headache. Headache. 2010;50(2):185-197.
99. Belanger S, Ma W, Chabot JG, Quirion R. Expression of calcitonin gene-related peptide, substance P and protein kinase C in cultured dorsal root ganglion neurons following chronic exposure to mu, delta and kappa opiates. Neuroscience. 2002;115(2):441-453.
100. Perrotta A, Serrao M, Sandrini G, et al. Sensitisation of spinal cord pain processing in medication overuse headache involves supraspinal pain control. Cephalalgia. 2010;30(3):272-284.
101. Ayzenberg I, Obermann M, Nyhuis P, et al. Central sensitization of the trigeminal and somatic nociceptive systems in medication overuse headache mainly involves cerebral supraspinal structures. Cephalalgia. 2006;26(9):1106-1114.
102. Munksgaard SB, Bendtsen L, Jensen RH. Modulation of central sensitisation by detoxifcation in MOH: Results of a 12-month detoxi-fcation study. Cephalalgia. 2013;33(7):444-453.
103. Cupini LM, Costa C, Sarchielli P, et al. Degradation of endocannabinoids in chronic migraine and medication overuse headache. Neurobiol Dis. 2008;30(2):186-189.
104. Rossi C, Pini LA, Cupini ML, Calabresi P, Sarchielli P. Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients: relation with serotonin levels. Eur J Clin Pharmacol. 2008;64(1):1-8.
105. Sarchielli P, Rainero I, Coppola F, et al. Involvement of corticotrophin-releasing factor and orexin-A in chronic migraine and medication-overuse headache: fndings from cerebrospinal fuid. Cephalalgia. 2008;28(7):714-722.
106. Chanraud S, Di Scala G, Dilharreguy B, Schoenen J, Allard M, Radat F. Brain functional connectivity and morphology changes in medication-overuse headache: Clue for dependence- related processes? Cephalalgia. Epub 2014 January 21.
107. Ferraro S, Grazzi L, Muffatti R, et al. In medication-overuse headache, fMRI shows long-lasting dysfunction in midbrain areas. Headache. 2012;52(10):1520-1534.
108. Grazzi L, Chiapparini L, Ferraro S, et al. Chronic migraine with medication overuse pre-post withdrawal of symptomatic medication: clinical results and fMRI correlations. Headache. 2010;50(6): 998-1004.
109. Fumal A, Laureys S, Di Clemente L, et al. Orbitofrontal cortex involvement in chronic analgesic-overuse headache evolving from episodic migraine. Brain. 2006;129 Pt 2:543-550.
110. Calabresi P, Cupini LM. Medication-overuse headache: similarities with drug addiction. Trends Pharmacol Sci. 2005;26(2):62-68.
111. Saper JR, Lake AE 3rd. Medication overuse headache: type I and type II. Cephalalgia. 2006;26(10):1262.
112. Lake AE. Medication overuse headache: biobehavioral issues and solutions. Headache. 2006;46 Suppl 3:S88-S97.
113. Bendtsen L, Evers S, Linde M, et al. EFNS guideline on the treatment of tension-type headache - report of an EFNS task force. Eur J Neurol. 2010;17(11):1318-1325.
114. Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force. Eur J Neurol. 2009;16(9):968-981.
115. Abbott F V, Fraser MI. Use and abuse of over-the-counter analgesic agents. J Psychiatry Neurosci. 1998;23(1):13-34.
116. Cooper RJ. Over-the-counter medicine abuse - a review of the literature. J Subst Use. 2013;18(2):82-107.
117. Cooper RJ. 'I can't be an addict. I am.' Over-the-counter medicine abuse: a qualitative study. BMJ Open. 2013;3(6).
118. Gossop M, Darke S, Griffths P, et al. The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction. 1995;90(5):607-614.
119. Grande RB, Aaseth K, Saltyte Benth J, Gulbrandsen P, Russell MB, Lundqvist C. The Severity of Dependence Scale detects people with medication overuse: the Akershus study of chronic headache. J Neurol Neurosurg Psychiatry. 2009;80(7): 784-789.
120. Lundqvist C, Aaseth K, Grande RB, Benth JS, Russell MB. The severity of dependence score correlates with medication overuse in persons with secondary chronic headaches. The Akershus study of chronic headache. Pain. 2010;148(3):487-491.
121. Lundqvist C, Benth JS, Grande RB, Aaseth K, Russell MB. An adapted Severity of Dependence Scale is valid for the detection of medication overuse: the Akershus study of chronic headache. Eur J Neurol. 2011;18(3):512-518.
122. Lundqvist C, Grande RB, Aaseth K, Russell MB. Dependence scores predict prognosis of medication overuse headache: a prospective cohort from the Akershus study of chronic headache. Pain. 2012;153(3):682-686.
123. Fuh JL, Wang SJ, Lu SR, Juang KD. Does medication overuse headache represent a behavior of dependence? Pain. 2005;119(1/3): 49-55.
124. Radat F, Creach C, Guegan-Massardier E, et al. Behavioral dependence in patients with medication overuse headache: a cross-sectional study in consulting patients using the DSM-IV criteria. Headache. 2008;48(7):1026-1036.
125. Lauwerier E, Paemeleire K, Van Damme S, Goubert L, Crombez G. Medication use in patients with migraine and medication-overuse headache: the role of problem-solving and attitudes about pain medication. Pain. 2011;152(6):1334-1339.
126. Galli F, Pozzi G, Frustaci A, et al. Differences in the personality profile of medication-overuse headache sufferers and drug addict patients: a comparative study using MMPI-2. Headache. 2011;51(8):1212-1227.
127. Sances G, Galli F, Anastasi S, et al. Medication-overuse headache and personality: a controlled study by means of the MMPI-2. Headache. 2010;50(2):198-209.
128. Ferrari A, Cicero AF, Bertolini A, Leone S, Pasciullo G, Sternieri E. Need for analgesics/drugs of abuse: a comparison between headache patients and addicts by the Leeds Dependence Questionnaire (LDQ). Cephalalgia. 2006;26(2):187-193.
129. Jonsson P, Jakobsson A, Hensing G, Linde M, Moore CD, Hedenrud T. Holding on to the indispensable medication - a grounded theory on medication use from the perspective of persons with medication overuse headache. J Headache Pain. 2013;14(1):43.
130. Saper JR, Hamel RL, Lake III AE. Medication overuse headache (MOH) is a biobehavioural disorder. Cephalalgia. 2005;25(7): 545-546.
131. Fuh JL, Wang SJ. Dependent behavior in patients with medication-overuse headache. Curr Pain Headache Rep. 2012;16(1):73-79.
132. Radat F, Lanteri-Minet M. What is the role of dependence-related behavior in medication-overuse headache? Headache. 2010;50(10): 1597-1611.
133. Rossi P, Faroni J V, Nappi G. Short-term effectiveness of simple advice as a withdrawal strategy in simple and complicated medication overuse headache. Eur J Neurol. 2011;18(3):396-401.
134. Diener HC. Detoxifcation for medication overuse headache is not necessary. Cephalalgia. 2012;32(5):423-427.
135. Olesen J. Detoxifcation for medication overuse headache is the primary task. Cephalalgia. 2012;32(5):420-422.
136. Hagen K, Albretsen C, Vilming ST, et al. Management of medication overuse headache: 1-year randomized multicentre open-label trial. Cephalalgia. 2009;29(2):221-232.
137. Linton-Dahlöf P, Linde M, Dahlöf C. Withdrawal therapy improves chronic daily headache associated with long-term misuse of headache medication: a retrospective study. Cephalalgia. 2000;20(7):658-662.
138. Katsarava Z, Fritsche G, Muessig M, Diener HC, Limmroth V. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology. 2001;57(9):1694-1698.
139. Krymchantowski AV, Moreira PF. Out-patient detoxification in chronic migraine: comparison of strategies. Cephalalgia. 2003;23(10):982-993.
140. Grazzi L, Andrasik F, Usai S, Bussone G. In-patient vs day-hospital withdrawal treatment for chronic migraine with medication overuse and disability assessment: results at one-year follow-up. Neurol Sci. 2008;29 Suppl 1:S161-S163.
141. Creach C, Frappe P, Cancade M, et al. In-patient versus out-patient withdrawal programmes for medication overuse headache: a 2-year randomized trial. Cephalalgia. 2011;31(11):1189-1198.
142. Gaul C, Bromstrup J, Fritsche G, Diener HC, Katsarava Z. Evaluating integrated headache care: a one-year follow-up observational study in patients treated at the Essen headache centre. BMC Neurol. 2011;11:124.
143. Boe MG, Mygland A, Salvesen R. Prednisolone does not reduce withdrawal headache: a randomized, double-blind study. Neurology. 2007;69(1):26-31.
144. Rabe K, Pageler L, Gaul C, et al. Prednisone for the treatment of withdrawal headache in patients with medication overuse headache: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2013;33(3):202-207.
145. Hagen K, Jensen R, Boe MG, Stovner LJ. Medication overuse headache: a critical review of end points in recent follow-up studies. J Headache Pain. 2010;11(5):373-377.
146. Grande RB, Aaseth K, Benth JS, Lundqvist C, Russell MB. Reduction in medication-overuse headache after short information. The Akershus study of chronic headache. Eur J Neurol. 2011;18(1): 129-137.
147. Rossi P, Di LC, Faroni J, Cesarino F, Nappi G, Di Lorenzo C. Advice alone vs structured detoxifcation programmes for medication overuse headache: a prospective, randomized, open-label trial in transformed migraine patients with low medical needs. Cephalalgia. 2006;26(9):1097-1105.
148. Rossi P, Faroni J V, Tassorelli C, Nappi G. Advice alone versus structured detoxifcation programmes for complicated medication overuse headache (MOH): a prospective, randomized, open-label trial. J Headache Pain. 2013;14(1):10.
149. Tassorelli C, Jensen R, Allena M, et al. A consensus protocol for the management of medication-overuse headache: evaluation in a multi-centric, multinational study. Cephalalgia. Epub 2014 February 20.
150. Diener HC, Dodick DW, Goadsby PJ, et al. Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse. Cephalalgia. 2009;29(10): 1021-1027.
151. Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804-814.
152. Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):793-803.
153. Sandrini G, Perrotta A, Tassorelli C, et al. Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study. J Headache Pain. 2011;12(4):427-433.
154. Silberstein SD, Blumenfeld AM, Cady RK, et al. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci. 2013;331(1/2):48-56.
155. Sarchielli P, Messina P, Cupini LM, et al. Sodium valproate in migraine without aura and medication overuse headache: a randomized controlled trial. Eur Neuropsychopharmacol. Epub 2014 April 5.
156. Zeeberg P, Olesen J, Jensen R. Discontinuation of medication overuse in headache patients: recovery of therapeutic responsiveness. Cephalalgia. 2006;26(10):1192-1198.
157. Martelletti P, Jensen RH, Antal A, et al. Neuromodulation of chronic headaches: position statement from the European Headache Federation. J Headache Pain. 2013;14(1):86.
158. Freeman JA, Trentman TL. Clinical utility of implantable neurostimula-tion devices in the treatment of chronic migraine. Med Devices (Auckl). 2013;6:195-201.
159. Boe MG, Salvesen R, Mygland A. Chronic daily headache with medication overuse: a randomized follow-up by neurologist or PCP. Cephalalgia. 2009;29(8):855-863.
160. Grazzi L, Andrasik F, D'Amico D, Usai S, Kass S, Bussone G. Disability in chronic migraine patients with medication overuse: treatment effects at 1-year follow-up. Headache. 2004;44(7): 678-683.
161. Katsarava Z, Limmroth V, Finke M, Diener HC, Fritsche G. Rates and predictors for relapse in medication overuse headache: a 1-year prospective study. Neurology. 2003;60(10):1682-1683.
162. Katsarava Z, Muessig M, Dzagnidze A, Fritsche G, Diener HC, Limmroth V. Medication overuse headache: rates and predictors for relapse in a 4-year prospective study. Cephalalgia. 2005;25(1): 12-15.
163. Zidverc-Trajkovic J, Pekmezovic T, Jovanovic Z, et al. Medication overuse headache: clinical features predicting treatment outcome at 1-year follow-up. Cephalalgia. 2007;27(11):1219-1225.
164. Boe MG, Salvesen R, Mygland A. Chronic daily headache with medication overuse: predictors of outcome 1 year after withdrawal therapy. Eur J Neurol. 2009;16(6):705-712.
165. Rossi P, Faroni J V, Nappi G. Medication overuse headache: predictors and rates of relapse in migraine patients with low medical needs. A 1-year prospective study. Cephalalgia. 2008;28(11):1196-1200.
166. Andrasik F, Grazzi L, Usai S, Kass S, Bussone G. Disability in chronic migraine with medication overuse: treatment effects through 5 years. Cephalalgia. 2010;30(5):610-614.
167. Ghiotto N, Sances G, Galli F, et al. Medication overuse headache and applicability of the ICHD-II diagnostic criteria: 1-year follow-up study (CARE I protocol). Cephalalgia. 2009;29(2):233-243.
168. Lai JT, Dereix JD, Ganepola R P, et al. Should we educate about the risks of medication overuse headache? J Headache Pain. 2014;15:10.
169. Fritsche G, Frettloh J, Huppe M, et al. Prevention of medication overuse in patients with migraine. Pain. 2010;151(2):404-413.